GlassScriptPhysician profile
Angela M Scott
NPI 1578870853
$11,984.58
in general payments reported to CMS, 2019-2025
59 companies · $3,592 in 2025
The $3,592 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.18 · 2022: $2,224 · 2023: $2,245 · 2024: $3,896 · 2025: $3,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,708 · Education: $25.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,707.88 |
| Education | $25.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $966.01 | 2023-2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $958.91 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $722.34 | 2022-2025 | Enhertu, Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $718.60 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $715.64 | 2022-2025 | Darzalex, Tecvayli, Carvykti |
| Lilly USA, LLC | $505.95 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Eisai INC. | $496.36 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $493.76 | 2022-2025 | Opdivo, Opdualag, Reblozyl |
| Genzyme Corporation | $471.26 | 2022-2025 | |
| Glaxosmithkline, LLC. | $457.09 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Pfizer INC. | $456.09 | 2022-2025 | |
| Gilead Sciences, INC. | $398.72 | 2022-2025 | Trodelvy |
| Abbvie INC. | $379.30 | 2023-2025 | |
| Genentech USA, INC. | $277.83 | 2022-2025 | Polivy, Phesgo, Perjeta |
| Incyte Corporation | $262.12 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $254.72 | 2022-2025 | Ninlaro, Iclusig |
| Celgene Corporation | $244.61 | 2022-2025 | Reblozyl, Opdualag |
| Daiichi Sankyo INC. | $204.91 | 2022-2025 | Enhertu, Injectafer |
| Stemline Therapeutics INC. | $195.18 | 2022-2025 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $183.30 | 2021-2023 | Imbruvica |
| Merz North America, INC. | $173.62 | 2024 | |
| Amgen INC. | $170.34 | 2022 | |
| Tempus Ai, INC | $170.02 | 2024-2025 | Xt Cdx |
| Beigene USA, INC. | $169.49 | 2022-2024 | Brukinsa, Tevimbra |
| Seagen INC. | $156.34 | 2022-2023 | Adcetris, Tukysa |
| Taiho Oncology, INC. | $133.53 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $126.75 | 2023-2025 | Ultomiris |
| G1 Therapeutics, INC. | $109.90 | 2022-2023 | Cosela |
| Coherus Oncology, INC. | $103.75 | 2021-2025 | Loqtorzi |
| Servier Pharmaceuticals LLC | $91.24 | 2022-2023 | |
| Astellas Pharma US INC | $76.08 | 2022-2025 | Xospata, Vyloy |
| Geron Corporation | $74.52 | 2025 | Rytelo |
| Regeneron Healthcare Solutions, INC. | $73.30 | 2022-2023 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $70.90 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $63.93 | 2022-2023 | Xarelto |
| Array Biopharma INC | $62.26 | 2025 | Braftovi, Mektovi, Tukysa |
| Sobi, INC | $60.55 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $56.31 | 2024 | Tavalisse, Rezlidhia |
| Emd Serono, INC. | $55.75 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.67 | 2025 | |
| Karyopharm Therapeutics INC. | $53.61 | 2024-2025 | Xpovio |
| Deciphera Pharmaceuticals INC. | $53.59 | 2022-2024 | Qinlock |
| Genmab U.S., INC. | $50.16 | 2024 | Epkinly |
| Morphosys, US INC. | $36.18 | 2022 | |
| Jazz Pharmaceuticals INC. | $33.69 | 2024-2025 | |
| Tersera Therapeutics LLC | $32.97 | 2022-2024 | Zoladex |
| Adaptive Biotechnologies Corporation | $32.88 | 2025 | Clonoseq |
| Agios Pharmaceuticals, INC. | $32.77 | 2023 | Pyrukynd |
| Springworks Therapeutics, INC. | $32.70 | 2024 | Ogsiveo |
| Pharmacosmos Therapeutics INC. | $31.85 | 2024 | Cosela, Monoferric |
| Sumitomo Pharma America, INC. | $24.92 | 2024 | Orgovyx |
| Shield Therapeutics INC | $23.27 | 2024 | |
| Syndax Pharmaceuticals, INC. | $21.80 | 2025 | |
| Aimmune Therapeutics, INC. | $20.66 | 2024 | |
| Beone Medicines USA, INC. | $19.61 | 2025 | Tevimbra |
| Aveo Pharmaceuticals, INC. | $18.77 | 2022 | |
| Mirati Therapeutics, INC. | $18.38 | 2023 | Krazati |
| Kyowa Kirin, INC. | $15.59 | 2022 | |
| Secura Bio, INC. | $15.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.